JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB209702

Goat Anti-Human IgG H&L (HRP) preadsorbed

Be the first to review this product! Submit a review

|

(2 Publications)

Suitable for IHC, WB, ELISA, ICC. Ideal for western blot. Preadsorbed to minimise non-specific binding and high background staining. Cited in 2 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Heavy & Light chains

Minimal cross-reactivity
Pre-adsorbed

Yes

Conjugation

HRP

Excitation/Emission
Applications

IHC, ELISA, WB, ICC

applications

Clonality

Polyclonal

Isotype

IgG

Immunogen

Full Length Protein corresponding to Human IGHG1. The exact immunogen used to generate this antibody is proprietary information.

P01857

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "IHC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/200 - 1/5000", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/5000 - 1/50000", "notes":"<p></p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/10000 - 1/100000", "notes":"<p></p>" }, "ICC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/200 - 1/5000", "notes":"<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
Antiserum was cross adsorbed using a monkey immunosorbent to remove cross reactive antibodies. The antibody to human IgG was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to HRP
Storage buffer
pH: 6.8 - 7.4 Preservative: 0.05% CMIT/MIT based preservative Constituents: 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

Additional targets

IGHG2,IGHG3,IGHG4

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Molecular therapy. Methods & clinical development 30:350-366 PubMed37637380

2023

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD.

Applications

Unspecified application

Species

Unspecified reactive species

Sharifah Iqball,Daniel K Beck,Gayathri Devarajan,Cheen P Khoo,Deirdre M O'Connor,Scott Ellis,Efrain Guzman,Kyriacos A Mitrophanous,Yatish Lad

mAbs 15:2220466 PubMed37314961

2023

A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoding Tan,Peng Fang,Kaiying Li,Meng You,Yuxia Cao,Hui Xu,Xiaohong Zhu,Lu Wang,Xin Wei,Haiying Wen,Wendi Li,Lei Shi,Xiaowei Sun,Dongan Yu,Huikai Zhu,Zhenzhen Wang,Datao Liu,Hui Shen,Wei Zhou,Maomao An
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com